ArticleNPJ digital medicine2026
A deep learning model to dynamically predict cancer-associated thromboembolism in large-scale healthcare systems.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Venous thromboembolism (VTE) is a leading cause of preventable death among patients undergoing systemic treatment for cancer. Studies suggest that treatment strategies such as direct oral anticoagulant administration can significantly reduce the likelihood of VTE. Therefore, identifying people at high risk is of critical importance. Leveraging electronic health records (EHRs) from the U.S. Veterans Affairs (VA) healthcare system, we developed a transformer model to predict VTE risk in 80,808 cancer patients following the initiation of systemic treatment. The model uses longitudinal diagnostic codes, laboratory values, and demographic data. The proposed transformer model dynamically predicts VTE risk in 3-month quarterly intervals over the year following systemic treatment, achieving progressively improved performance across quarters (AUC: 0.68-0.77). The model is similarly performant on the external validation cohort from the Harris Health System (HHS) with 9752 patients (AUC: 0.68-0.74). By improving its predictions as a patient's history evolves, this dynamic model surpasses prior static risk scores and better supports actionable decisions deeper into the treatment course.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.